Molecular Characterization of Bladder Cancer

Area of Science:

• Oncology
• Genomics
• Molecular Biology

Background:

• Bladder cancer (BCa) management has seen limited evolution over two decades.
• Clinicians traditionally overlook molecular characteristics in BCa treatment decisions.
• Recent breakthroughs in molecular understanding and systemic therapies are transforming BCa care.

Purpose of the Study:

• To review key developments in bladder cancer molecular profiling.
• To discuss the impact of molecular advances on BCa management.
• To explore future directions in BCa treatment guided by molecular data.

Main Methods:

• Utilizing next-generation sequencing (NGS) for molecular subtyping of bladder cancer.
• Analyzing international consortium data for muscle-invasive BCa (MIBC) classification.
• Evaluating molecular stratification for non-muscle invasive BCa (NMIBC).

Main Results:

• NGS has significantly advanced the understanding of MIBC and NMIBC.
• MIBC molecular subtyping identified five classes, aiding treatment response prediction.
• NMIBC molecular subtyping offers superior stratification compared to histopathology alone.
• New actionable targets are emerging for refractory BCa cases.

Conclusions:

• Molecular characterization is rapidly advancing bladder cancer understanding.
• Emerging molecular data is poised to alter current treatment paradigms.
• Future BCa management will increasingly integrate molecular testing for personalized therapy.